BioPharma

The main reason for delays and extensions is that sponsors submit their applications too soon.

How can pharmaceutical companies successfully apply advanced analytics?

In the case of one country, demands made by the pharmaceutical giant led to a three-month delay in a vaccine deal being agreed.

Though they were warned, pharmaceutical companies refused to invest in coronavirus research until it was too late.

The top biopharmaceutical investors in the world.

Vaccines and therapeutics for Covid-19 have been an unexpected windfall for the drug industry, but Wall Street is less enthusiastic about cash windfalls.

In dollar terms, much of the sales came at a single company, Moderna, maker of one of two Covid-19 vaccines authorized for use in the U.S. Executives and a director there sold more than $321 million of their stock in more than 700 transactions.

The opioids crisis that has taken hundreds of thousands of American lives has received less attention in the pandemic, but drug overdoses and deaths have grown during the last year.

Are manufacturing method patents — patents not on a pharmaceutical drug itself, but on a method of production of a drug — warranted intellectual property protections, or groundless obstacles to competition?

Statement by Executive Vice-President Vestager on the Commission decision to accept commitments by Aspen to reduce prices for six off-patent cancer medicines by 73% addressing excessive pricing concerns.

Bristol-Myers and Sanofi still face a similar lawsuit over Plavix by the state of New Mexico.

Big pharma has been essential in the race to fight Covid-19. In exchange, their work to end Covid-19 has rewarded pharmaceutical companies rather handsomely.

Four companies that agreed to pay a combined $26 billion to settle claims about their roles in the U.S. opioid crisis plan to deduct some of those costs from their taxes and recoup around $1 billion apiece.

A Mount Sinai Morningside and Mount Sinai West Department of Medicine Grand Rounds presented by Deborah Korenstein, MD, Chief, General Medicine Service, Memorial Sloan Kettering Cancer Center.

A victory for Regeneron Pharmaceuticals Inc and Sanofi SA, which sell a rival drug.